Back to search

Article

ERK1/2 Inhibition Alleviates Noise-Induced Hearing Loss While Tempering Down the Immune Response

2023-10-20

Abstract excerpt

Noise-induced hearing loss (NIHL) is a major cause of hearing impairment, yet no FDA-approved drugs exist to prevent it. Targeting the mitogen activated protein kinase (MAPK) cellular pathway has emerged as a promising approach to attenuate NIHL. Tizaterkib is an orally bioavailable, highly specific ERK1/2 inhibitor, currently in Phase-1 anticancer clinical trials. Here, we tested tizaterkib’s efficacy against per...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f1dccf81-cb05-5e5d-879a-64924659ab5b
DOI
10.1101/2023.10.18.563007
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
ERK1/2 Inhibition Alleviates Noise-Induced Hearing Loss While Tempering Down the Immune ResponseDOI 10.1101/2023.10.18.563007
Select a neighboring publication to make it the new centre.